Logo image of HCWB

HCW BIOLOGICS INC (HCWB) Stock Fundamental Analysis

NASDAQ:HCWB - Nasdaq - US40423R2040 - Common Stock - Currency: USD

8.69  -0.49 (-5.34%)

Fundamental Rating

1

HCWB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. HCWB has a bad profitability rating. Also its financial health evaluation is rather negative. HCWB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HCWB has reported negative net income.
HCWB had a negative operating cash flow in the past year.
HCWB had negative earnings in each of the past 5 years.
HCWB had a negative operating cash flow in each of the past 5 years.
HCWB Yearly Net Income VS EBIT VS OCF VS FCFHCWB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

HCWB's Return On Assets of -99.30% is on the low side compared to the rest of the industry. HCWB is outperformed by 76.65% of its industry peers.
Industry RankSector Rank
ROA -99.3%
ROE N/A
ROIC N/A
ROA(3y)-72.93%
ROA(5y)-57.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HCWB Yearly ROA, ROE, ROICHCWB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

HCWB has a Gross Margin of 37.38%. This is in the better half of the industry: HCWB outperforms 74.33% of its industry peers.
The Profit Margin and Operating Margin are not available for HCWB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HCWB Yearly Profit, Operating, Gross MarginsHCWB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

HCWB does not have a ROIC to compare to the WACC, probably because it is not profitable.
HCWB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HCWB has been increased compared to 5 years ago.
The debt/assets ratio for HCWB is higher compared to a year ago.
HCWB Yearly Shares OutstandingHCWB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
HCWB Yearly Total Debt VS Total AssetsHCWB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

HCWB has an Altman-Z score of -8.51. This is a bad value and indicates that HCWB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.51, HCWB is doing worse than 72.01% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.51
ROIC/WACCN/A
WACC9.36%
HCWB Yearly LT Debt VS Equity VS FCFHCWB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.19 indicates that HCWB may have some problems paying its short term obligations.
With a Current ratio value of 0.19, HCWB is not doing good in the industry: 96.43% of the companies in the same industry are doing better.
A Quick Ratio of 0.19 indicates that HCWB may have some problems paying its short term obligations.
The Quick ratio of HCWB (0.19) is worse than 96.26% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
HCWB Yearly Current Assets VS Current LiabilitesHCWB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

HCWB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -66.67%.
HCWB shows a decrease in Revenue. In the last year, the revenue decreased by -9.53%.
Measured over the past years, HCWB shows a very negative growth in Revenue. The Revenue has been decreasing by -11.50% on average per year.
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.33%
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y-11.5%
Revenue growth 5YN/A
Sales Q2Q%-70.17%

3.2 Future

Based on estimates for the next years, HCWB will show a small growth in Earnings Per Share. The EPS will grow by 3.34% on average per year.
The Revenue is expected to grow by 141.38% on average over the next years. This is a very strong growth
EPS Next Y16.94%
EPS Next 2Y9.48%
EPS Next 3Y6.65%
EPS Next 5Y3.34%
Revenue Next Year368.22%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y141.38%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HCWB Yearly Revenue VS EstimatesHCWB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2028 2029 2030 200M 400M 600M
HCWB Yearly EPS VS EstimatesHCWB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HCWB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HCWB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HCWB Price Earnings VS Forward Price EarningsHCWB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCWB Per share dataHCWB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.48%
EPS Next 3Y6.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HCWB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HCW BIOLOGICS INC

NASDAQ:HCWB (5/21/2025, 12:27:45 PM)

8.69

-0.49 (-5.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/dmh
Earnings (Next)N/A N/A
Inst Owners7.02%
Inst Owner Change-63.07%
Ins Owners40.57%
Ins Owner Change15.4%
Market Cap9.73M
Analysts82.86
Price Target122.4 (1308.52%)
Short Float %N/A
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3900%
PT rev (3m)3900%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-3900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.79
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-28
EYN/A
EPS(NY)-22.44
Fwd EYN/A
FCF(TTM)-12.94
FCFYN/A
OCF(TTM)-12.7
OCFYN/A
SpS2.29
BVpS-6.04
TBVpS-6.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.38%
FCFM N/A
ROA(3y)-72.93%
ROA(5y)-57.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.09%
Cap/Sales 10.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -8.51
F-Score2
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)665.42%
Cap/Depr(5y)407.44%
Cap/Sales(3y)127.14%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.33%
EPS Next Y16.94%
EPS Next 2Y9.48%
EPS Next 3Y6.65%
EPS Next 5Y3.34%
Revenue 1Y (TTM)-9.53%
Revenue growth 3Y-11.5%
Revenue growth 5YN/A
Sales Q2Q%-70.17%
Revenue Next Year368.22%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y141.38%
EBIT growth 1Y-12.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.81%
OCF growth 3YN/A
OCF growth 5YN/A